Thirty drugs will be purchased without volume, with no finalists suspended.

"Pharmaceutical Network Industry Dynamics" August 3, Wuhan City Pharmaceuticals Joint Procurement Office on the release of "Wuhan City 2020 key monitoring of reasonable drug bargaining implementation rules" and "key monitoring of reasonable drug bargaining drug catalog" notice, will be 30 clinical large varieties of non-volume bargaining procurement.
From these 30 clinical large varieties, including neural glycoside lipids, cerebroside carnosine, Oxiracetam and other 20 countries focus on monitoring the rational drug list of drugs, but also 10 provincial and Wuhan medical institutions focus on monitoring drugs (chemical Medicine, Chinese medicine are listed), among them, the Chinese medicine species involved in ginseng injection, lugua polypeptide injection, placental polypeptide injection, acrylamide glutamine, injection thrombosis (thrombosis injection) and so on.
it is understood that the country listed 20 key monitoring varieties in the context of restricted use, in recent years the market has shown a marked contraction.
meters intranet data show that in 2019 in China's public medical institutions terminal, 14 of these 20 varieties of products sales growth rate is negative, of which single salivary acid glucosin nerve glycoside sodium injection, injection of compound coenzyme, injection of sodium creacortic acid decline of more than 30%.
of Chinese medicine injections is also not very good, because many places to include it in the local key monitoring list, resulting in a declining market size.
2018, sales of Chinese medicine injections at the end of china's public medical institutions fell by 8.54 percent, while sales of Chinese medicine in key cities fell by 12.88 percent, according to data released last year.
This time, Wuhan City into the scope of non-volume bargaining procurement of Chinese medicine injections are also large varieties, such as injection thrombosis sales in 2018 reached 6.357 billion yuan, ranking first in the 2018 list of Chinese medicine injection products in public medical terminals in China.
with wuhan city without volume bargaining procurement, the industry expects the variety or has to carry out price reductions to preserve the market.
In accordance with the bargaining method proposed by Wuhan City, the expert group agreed that the high limit price (effective quotation) of this key monitoring variety is 0.7 times the low price of the national provincial-level hanging network price of the enterprise variety, and the quotation of the high limit price is invalid.
With the generic name, the same dosage form, the same specifications of drug qualified declaration enterprises greater than or equal to 2 for Group A, low effective quotation enterprises to be shortlisted;
It is not difficult to see from the bargaining method, a sharp price reduction is inevitable, in the fierce price competition, the relevant enterprises may face greater pressure, but if not shortlisted, it means the loss of the entire Hubei Province medical institutions market.
In addition, Wuhan City will refer to the "Wuhan City drug centralized volume procurement catalog classification measures", the key monitoring of the variety of dosage forms and product regulations for the combined group, the same reporting enterprises can only select a retail quantity packaging product rules to participate in the quotation, after the finalists in principle to supply this packaging product regulations, and in accordance with the preparation unit quotation and coefficient multiplied as the purchase price of this product regulation packaging.
this also means that enterprises can only participate in a product standard quotation, after the election can only supply this product rule, so whether the enterprise can seize the main product regulation variety of the market is very critical.
.